Matrix Laboratories receives FDA tentative approval for Efavirenz NDA under PEPFAR

December 27, 2015

The report also found "[o]ther diseases, such as Chagas, kala-azar [visceral leishmaniasis], sleeping sickness, and Buruli ulcer continue to be neglected, with very few new commitments to expanding access to available treatment or carrying out research for much needed newer and more effective drugs," Mail & Guardian writes (12/22).

VOA News analyzes the findings of the report (DeCapua, 12/21).

This article is republished with kind permission from our friends at The Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, debates and discussions. The Kaiser Daily Health Policy Report is published for Kaisernetwork, a free service of The Henry J. Kaiser Family Foundation. 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.